Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237328 · ClinicalTrials.gov registry record
Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
A clinical trial of Thrombosis, sponsored by Duke University.
- Completed
- Registry status
- 1,015
- Enrollment target
- 4
- Study locations
NCT00237328: Completed study of Thrombosis, sponsored by Duke University.
NCT00237328 is a study of Thrombosis that has completed, run by Duke University. The registered enrollment target is 1,015 participants, above the 434-participant average among 28 other Thrombosis trials with a reported enrollment target (134% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00237328, a study of Thrombosis, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 1,015 participants
- Enrollment target
- 4
- Study locations
Study Summary
Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage for a potential heart attack or stroke. The purpose of this study is to evaluate how often an immune response to heparin leads to the formation of blood clots in individuals who have had heart surgery.
Conditions Studied
Interventions
- DRUG Heparin
Study Locations (4)
North Carolina
- University of North Carolina - Chapel Hill
- Duke University Medical Center - Durham
Minnesota
- Mayo Clinic, Rochester - Rochester
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-07 |
What the finished NCT00237328 record still lists
NCT00237328 is an observational study that tracks outcomes without assigning an intervention. Its 1,015 participants enrollment target places it among the larger protocols in the corpus, above the 434-participant average among 28 other Thrombosis trials with a reported enrollment target (134% higher).
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Heparin is the first listed.
NCT00237328 reports a single indexed study location in North Carolina, Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00237328 about?
NCT00237328 is a clinical study titled "Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery". Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage f...
What is the current status of trial NCT00237328?
This trial is currently completed. The enrollment target is 1,015 participants. The study started on 2006-06. Estimated completion is 2012-07.
What conditions does trial NCT00237328 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT00237328?
The interventions under investigation include: Heparin (DRUG).
Who is sponsoring clinical trial NCT00237328?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00237328 being conducted?
This trial has 4 study locations across Minnesota, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00237328's enrollment target sits among peer trials
1,015 5th of 28 higher than 24 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
-
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia